论文部分内容阅读
对２５例溃疡性结肠炎（ＵＣ）患者ＰＢＭＣ体外诱生白细胞介素６（ＩＬ６）水平进行测定，同时与２０例健康志愿者（ＨＣ）进行对照，结果ＵＣ组与ＨＣ组ＩＬ６活性分别为２６１４８±８２０１Ｕ／ｍｌ和１００．００±５７．６５Ｕ／ｍｌ，Ｐ＜０．００１。ＵＣ组静止期与轻、中、重度３组比较，ＩＬ６活性依次为１２１．０６±４３．００Ｕ／ｍｌ，２４０．２３±６１．６０Ｕ／ｍｌ，２７５．８３±７８．４６Ｕ／ｍｌ，３１５．００±１４２．９２Ｕ／ｍｌ。Ｐ分别＜００２，００２，０００１。而静止期与ＨＣ相比，Ｐ＞００５。按病变累及部位，全结肠组与左半结肠组ＩＬ６活性分别为３１２３３±１０７．３４Ｕ／ｍｌ，２４４．８８±６９．９７Ｕ／ｍｌ，Ｐ＞００５。说明ＵＣ活动期患者ＩＬ６活性明显高于对照与静止期患者，且随病情加重呈上升趋势。ＩＬ６活性与病变累及部位无关。提示：观察ＩＬ６活性，可反映疾病转归。针对ＩＬ６活性进行调控，为ＵＣ治疗新动向。
In 25 cases of UC patients PBMC induced IL-6 (IL 6) levels were measured at the same time with 20 healthy volunteers (HC) were compared, the results of UC and HC HC 6 activity were 26148 ± 8201 U / ml and 100.00 ± 57.65 U / ml respectively, P <0.001. The activity of IL6 was 121.06 ± 43.00U / ml, 240.23 ± 61.60U / ml, 275.83 ± 78.46U / ml, 315.00 ± 142.92 U / ml. P <0 02,0 02,0 001. Compared with HC, the resting period was P> 005. According to the lesion involvement site, the activities of IL6 in the whole colon and left colon were 31233 ± 107.34U / ml and 244.88 ± 69.97U / ml, respectively, P> 005. The activity of IL 6 in patients with active UC was significantly higher than the control and quiescent patients, and with the increase of the disease is on the rise. IL 6 activity and involvement of the lesion has nothing to do. Tip: Observing IL 6 activity, can reflect the disease outcome. For the regulation of IL 6 activity for the treatment of UC new trends.